Myambutol (Ethambutol Hydrochloride)

Ethambutol Hydrochloride, the active ingredient in Myambutol, is an antimyobacterial presented as an oral dosage form for systemic use. It is employed in the treatment of tuberculosis, typically as part of combination therapy, and is indicated for patients with active Mycobacterium tuberculosis infection.

GNH USA supplies Myambutol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global health programmes, including public and private sector purchasers.

Ethambutol is an antitubercular agent used in combination regimens targeting Mycobacterium tuberculosis infections.

- Pulmonary tuberculosis: contributes to bacterial clearance when combined with other first‑line drugs. - Extrapulmonary tuberculosis: aids in treating disease sites such as lymph nodes, pleura, or meninges as part of multidrug therapy. - Miliary tuberculosis: provides bacteriostatic activity across disseminated infection when used in standard combination protocols.

Ethambutol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Visual disturbances (blurred vision, color vision changes) - Nausea - Vomiting - Abdominal pain - Headache - Rash

Serious or Rare Side Effects: - Optic neuritis leading to permanent vision loss - Severe allergic reactions including anaphylaxis - Hepatic dysfunction (elevated transaminases, hepatitis) - Peripheral neuropathy - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe dizziness or loss of coordination

When prescribing Ethambutol, clinicians should observe several precautionary measures to minimize risk.

- Baseline visual assessment: perform ophthalmologic exam before therapy and monitor periodically. - Renal function monitoring: adjust dose in patients with impaired clearance. - Hepatic impairment: use with caution and monitor liver enzymes. - Known hypersensitivity: avoid in patients with documented allergy to ethambutol. - Elderly patients: start at lower dose and observe for toxicity. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Ethambutol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Isoniazid: increased risk of optic neuritis when combined. - Rifampicin: reduces ethambutol plasma concentrations, potentially decreasing effectiveness. - Streptomycin: heightened neurotoxic potential when used together.

Moderate Interactions (Monitor Closely): - Pyrazinamide: may increase hepatotoxic risk. - Fluoroquinolones: additive risk of tendon disorders. - Antiretroviral agents (e.g., protease inhibitors): may affect drug levels. - Diuretics: can exacerbate electrolyte disturbances. - Vitamin supplements (pyridoxine): monitor for overlapping toxicity.